SULFAMETHOXAZOLE; TRIMETHOPRIM - Generic Drug Details

What are the generic sources for sulfamethoxazole; trimethoprim and what is the scope of freedom to operate?

Sulfamethoxazole; trimethoprim is the generic ingredient in twenty-two branded drugs marketed by Sun Pharm Inds Inc, Monarch Pharms, Abraxis Pharm, Bedford, Hikma, Hospira, Pharmobedient, Somerset, Teva Pharms Usa, Watson Labs, Sun Pharm Industries, Ani Pharms, Aurobindo Pharma, Chartwell Molecular, Lupin Ltd, Novitium Pharma, Prasco, Teva, Pharm Assoc, Usl Pharma, Alpharma Us Pharms, Naska, Novel Labs Inc, Aiping Pharm Inc, Amneal Pharms Ny, Chartwell Molecules, Fosun Pharma, Glenmark Pharms Ltd, Heather, Interpharm, Martec Usa Llc, Mutual Pharm, Pliva, Roxane, Vista Pharms, Heritage Pharma Avet, Superpharm, and Shionogi, and is included in sixty-five NDAs. Additional information is available in the individual branded drug profile pages.

Forty-seven suppliers are listed for this compound.

Summary for SULFAMETHOXAZOLE; TRIMETHOPRIM

US Patents:	0
Tradenames:	22
Applicants:	38
NDAs:	65
Finished Product Suppliers / Packagers:	47
Raw Ingredient (Bulk) Api Vendors:	27
Clinical Trials:	163
DailyMed Link:	SULFAMETHOXAZOLE; TRIMETHOPRIM at DailyMed

Recent Clinical Trials for SULFAMETHOXAZOLE; TRIMETHOPRIM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE4
Hospital Civil de Guadalajara	PHASE2

See all SULFAMETHOXAZOLE; TRIMETHOPRIM clinical trials

Pharmacology for SULFAMETHOXAZOLE; TRIMETHOPRIM

Drug Class	Dihydrofolate Reductase Inhibitor Antibacterial Sulfonamide Antimicrobial
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Cytochrome P450 2C9 Inhibitors Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for SULFAMETHOXAZOLE; TRIMETHOPRIM

J01EA	Trimethoprim and derivatives
J01E	SULFONAMIDES AND TRIMETHOPRIM
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01EC	Intermediate-acting sulfonamides
J01E	SULFONAMIDES AND TRIMETHOPRIM
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01EE	Combinations of sulfonamides and trimethoprim, incl. derivatives
J01E	SULFONAMIDES AND TRIMETHOPRIM
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for SULFAMETHOXAZOLE; TRIMETHOPRIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	090624-002	Feb 16, 2010	AB	RX	No	No
Novitium Pharma	SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	214330-001	Feb 8, 2022	AB	RX	No	No
Pliva	SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	070216-001	Sep 10, 1985		DISCN	No	No
Fosun Pharma	SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	018598-003	May 19, 1982		DISCN	No	No
Aurobindo Pharma	SULFAMETHOXAZOLE AND TRIMETHOPRIM	sulfamethoxazole; trimethoprim	SUSPENSION;ORAL	091348-001	Jun 8, 2010	AB	RX	No	Yes

Expired US Patents for SULFAMETHOXAZOLE; TRIMETHOPRIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982
Sun Pharm Industries	BACTRIM DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017377-002	Approved Prior to Jan 1, 1982
Monarch Pharms	SEPTRA DS	sulfamethoxazole; trimethoprim	TABLET;ORAL	017376-002	Approved Prior to Jan 1, 1982
Sun Pharm Inds Inc	BACTRIM	sulfamethoxazole; trimethoprim	INJECTABLE;INJECTION	018374-001	Approved Prior to Jan 1, 1982
Sun Pharm Industries	BACTRIM	sulfamethoxazole; trimethoprim	TABLET;ORAL	017377-001	Approved Prior to Jan 1, 1982

Market Dynamics and Financial Trajectory of Sulfamethoxazole and Trimethoprim

Last updated: February 19, 2026

What is the current market size for sulfamethoxazole and trimethoprim?

The global sulfamethoxazole and trimethoprim (SMX/TMP) market was valued at approximately $600 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 3.2% from 2023 to 2030, reaching roughly $840 million by 2030 [1].

What are the key drivers shaping this market?

Rise in bacterial infections

Increasing prevalence of urinary tract infections (UTIs), respiratory tract infections, and opportunistic infections in immunocompromised populations (particularly HIV/AIDS patients) sustains demand.

Antibiotic resistance patterns

Global emergence of drug-resistant bacteria has caused shifts in prescribing practices. While resistance to SMX/TMP is rising, it remains a preferred treatment in certain regions due to low cost and established efficacy.

Regulatory and patent landscape

Generic manufacturers dominate the market due to patent expirations dating back over a decade. Limited pipeline activity for new fixed-dose combinations constrains innovation.

Healthcare infrastructure and accessibility

Growing healthcare access in African and Asian markets leads to increased prescription of affordable antibiotics like SMX/TMP.

What are the major market players?

Company	Market Share (2022)	Key Products	Notes
Teva Pharmaceuticals	35%	SXT (sulfamethoxazole and trimethoprim)	Global presence, low-cost generics
Mylan (now part of Viatris)	25%	TMP-SMX tablets	Extensive distribution network
Sun Pharmaceutical Industries	15%	Generic formulations	Focused on emerging markets
Others	25%	Various regional players	Fragmented segment

How does pricing influence market dynamics?

Pricing for generic SMX/TMP formulations in developed markets averages $0.10–$0.20 per tablet. Price competition among generic firms sustains affordability but limits profit margins. In emerging markets, prices are lower, increasing accessibility but reducing profit potential for manufacturers.

What are the regulatory challenges impacting market growth?

• Approval delays for new formulations constrain innovation.
• Antibiotic stewardship policies in Europe and North America increasingly restrict off-label use.
• Resistance surveillance influences prescribing guidelines, leading to fluctuating demand.

What are the financial prospects for manufacturers?

Manufacturers with established production facilities and extensive distribution networks benefit from steady cash flows. Patent expirations have led to a highly commoditized market, restricting pricing power. Future revenue depends heavily on geographic expansion, particularly into untapped African and Asian markets where demand is rising.

How might emerging trends affect future market conditions?

Development of combination therapies

Limited investment in novel fixed-dose combinations diminishes innovation. However, some companies explore formulations with enhanced tolerability or broader coverage.

Antimicrobial stewardship and resistance management

Policies aimed at reducing unnecessary antibiotic use could decrease demand in some regions but also incentivize precise, clinically justified prescriptions, potentially offsetting declines.

Supply chain and manufacturing costs

Fluctuations in raw material costs, particularly for active pharmaceutical ingredients (APIs), influence profit margins. Shift toward local API production may reduce dependency on imports.

Summary of market risks

• Resistance diminishing clinical efficacy.
• Regulatory tightening reducing prescription volumes.
• Price erosion driven by generic competition.

Key financial metrics comparison

Year	Market Size (USD millions)	CAGR	Estimated Market Share of Top 3 Players
2022	600	3.2%	75%
2023	618	3.2%	75%
2030	840	3.2%	N/A

Key Takeaways

• The overall market for sulfamethoxazole and trimethoprim remains steady due to widespread use in bacterial infections and expanding healthcare access in emerging regions.
• Patent expirations have made the market predominantly generic, limiting profit margins.
• Resistance patterns and antibiotic stewardship policies influence future market viability.
• Growth potential centers on geographic expansion, especially in high-demand, underserved regions.
• Innovation in formulations is limited but could provide niche opportunities if aligned with stewardship guidelines.

FAQs

1. Which regions drive the most demand for sulfamethoxazole and trimethoprim?

The Asia-Pacific and African regions exhibit the highest growth due to increasing access to affordable healthcare and high disease burdens.

2. How does antimicrobial resistance impact market sustainability?

Rising resistance reduces clinical efficacy, leading to stricter prescribing guidelines and possible demand reduction, especially if alternative therapies emerge.

3. Are there new formulations in development?

Currently, no major pipeline candidates for novel fixed-dose formulations are in advanced clinical stages; most focus on generic versions.

4. What role do government policies play?

Policies emphasizing antimicrobial stewardship and resistance management can restrict use, impacting revenues. Conversely, government procurement programs in emerging markets support steady demand.

5. How do pricing trends affect profitability?

Intense generic competition keeps prices low, constraining profit margins. However, high-volume sales in expanding markets can offset low unit prices, sustaining cash flows.

---

References

[1] Market Research Future (2022). Global sulfamethoxazole and trimethoprim market report.